The Stromal and Immune Landscape of Colorectal Cancer Progression during Anti-EGFR Therapy

Research output: Contribution to journalArticlepeer-review

Abstract

In this issue of Cancer Cell, Woolston et al. show that colorectal cancers that become refractory to initially effective anti-EGFR therapy contain an abundance of stromal and immune cells, irrespective of the contextual presence of resistance-conferring mutations. This reconfiguration puts forward therapeutic opportunities for patients who relapse on EGFR-targeting treatment.

Original languageEnglish
Pages (from-to)1-3
Number of pages3
JournalCancer Cell
Volume36
Issue number1
DOIs
Publication statusPublished - Jul 8 2019

Fingerprint Dive into the research topics of 'The Stromal and Immune Landscape of Colorectal Cancer Progression during Anti-EGFR Therapy'. Together they form a unique fingerprint.

Cite this